Truist lowered the firm’s price target on Teleflex to $219 from $240 and keeps a Hold rating on the shares after its Q1 results and narrowed FY24 guidance. The company reported a “good” margin beat, but its EPS guide only nudges higher at the bottom end of the range, though the management’s hesitation to raise the outlook was more reflective of conservatism, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TFX:
- Teleflex Inc to Reveal Q1 Financial Results on May 2
- Teleflex narrows 2024 adjusted EPS view to $13.60-$13.95 from $13.55-$13.95
- Teleflex reports Q1 adjusted EPS $3.21, consensus $3.07
- Teleflex Announces Multiple Clinical and Real-World Evidence Studies to Be Highlighted at the 2024 American Urological Association Annual Meeting
- Teleflex Announces the Limited Market Release of the Wattson™ Temporary Pacing Guidewire